Inventiva SACA

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

27 7 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

24 6 2023 02:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

13 6 2023 17:00:00 提供 Nasdaq GlobeNewswire

Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients  

08 6 2023 02:30:00 提供 Nasdaq GlobeNewswire

Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

07 6 2023 16:00:00 提供 Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023

26 5 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

25 5 2023 16:00:00 提供 Nasdaq GlobeNewswire

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023

25 5 2023 09:50:00 提供 Nasdaq GlobeNewswire

Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

16 5 2023 16:00:00 提供 Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023

04 5 2023 02:31:00 提供 Nasdaq GlobeNewswire

Combined General Meeting of May 25, 2023. Availability of the preparatory documents

04 5 2023 02:30:00 提供 Nasdaq GlobeNewswire

Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F

30 3 2023 08:19:15 提供 Nasdaq GlobeNewswire

Inventiva reports its 2022 full-year results

29 3 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

23 3 2023 17:00:00 提供 Nasdaq GlobeNewswire

Correction: Inventiva reports preliminary financial results for Full-Year 2022¹

14 2 2023 16:00:00 提供 Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

30 1 2023 16:00:00 提供 Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of January 25, 2023

26 1 2023 02:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

04 1 2023 16:00:00 提供 Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of December 19, 2022

03 1 2023 02:35:00 提供 Nasdaq GlobeNewswire

Combined General Meeting of January 25, 2023 - Availability of the preparatory documents

03 1 2023 02:30:00 提供 Nasdaq GlobeNewswire